Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

This subset analysis of data from two phase III studies in patients with relapsed or refractory multiple myeloma (MM) evaluated the benefit of initiating lenalidomide plus dexamethasone at first relapse. Multivariate analysis showed that fewer prior therapies, along with β(2)-microglobulin (≤2.5 mg/...

Descripción completa

Detalles Bibliográficos
Autores principales: Stadtmauer, Edward A, Weber, Donna M, Niesvizky, Ruben, Belch, Andrew, Prince, Miles H, San Miguel, Jesús F, Facon, Thierry, Olesnyckyj, Marta, Yu, Zhinuan, Zeldis, Jerome B, Knight, Robert D, Dimopoulos, Meletios A
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704925/
https://www.ncbi.nlm.nih.gov/pubmed/19302559
http://dx.doi.org/10.1111/j.1600-0609.2009.01257.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704925/
https://www.ncbi.nlm.nih.gov/pubmed/19302559
http://dx.doi.org/10.1111/j.1600-0609.2009.01257.x

Ejemplares similares